 CAMBRIDGE, Mass., May 27, 2021 GLOBE NEWSWIRE -- Werewolf Therapeutics, Inc. Nasdaq: HOWL, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET. 